Therefore, we performed further experiments to explore the role of high-concentration PGD2 in drug response to venetoclax, which was the inhibitor of Bcl-2 and displayed greatly anti-tumor effects in hematological cancers. The gene discussed is BCL2; the disease is neoplasm.